S19-279 Nanoparticles Containing Toll-Like Receptor Agonist for Enhanced Efficacy of Immune Checkpoint Blockade Stanford inventors have developed a nanoparticle containing the toll-like receptor agonist (TLR7-NP) that elicits a potent anti-tumor immune response in multiple cancer types without inducing undesired systemic inflammation and toxicity. Qian Yin Mark Davis